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Background
Immune checkpoint inhibitors, particularly those target-
ing CTLA-4 and PD-1, are transforming the way cancer
is treated. However, these therapies do not benefit all
patients and frequently cause significant immune-related
adverse events. Therefore, prognostic biomarkers that
identify positively-responding patients, early in the
course of therapy, are essential for guiding treatment
decisions and improving patient outcomes.
Methods
In this study, we present evidence that shortly after initi-
ating combination PD-1/CTLA-4 blockade, there is a
transient increase in the frequency of pro-inflammatory
and cytotoxic lymphocytes in peripheral blood, and the
dynamics of this shift correlate with survival outcomes
in multiple murine models.
Results
Specifically, we observed that 1) the relative frequency of
cytotoxic CD8 T cells among peripheral lymphocytes and
2) the pro-inflammatory capacity of peripheral lymphocytes
are both predictive for outcomes at an early time point.
Surprisingly, robust correlations between peripheral lym-
phocyte markers and outcomes were limited to CD8 T cell
populations. In general, the expression of potential biomar-
kers on peripheral CD4 T cells, including ICOS and FoxP3,
were poorly correlated with outcomes in this study.
Conclusions
Overall, these findings suggest that elements of
the near-term peripheral immune response to dual
anti-PD-1/anti-CTLA-4 therapy associated with cytotoxic
lymphocyte function may provide unique prognostic
biomarkers for therapeutic outcomes.
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